Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term ...

Regeneron Pharmaceuticals has recently launched a Phase 2 trial, testing the waters with a potential breakthrough in melanoma ...

Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. Yet another ...

Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% gain.

CWM LLC has more than doubled its stake in Regeneron Pharmaceuticals, snapping up an additional 2,007 shares to now hold a ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Review the current Regeneron Pharmaceuticals Inc (REGN:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if REGN is the best investment for you.